GENMAB A/S/S (OTCMKTS:GMXAY – Get Free Report) dropped 0.7% during mid-day trading on Friday . The stock traded as low as $31.37 and last traded at $31.50. Approximately 902,270 shares changed hands during mid-day trading, an increase of 1,758% from the average daily volume of 48,553 shares. The stock had previously closed at $31.71.
GENMAB A/S/S Trading Up 2.8%
The business’s 50-day moving average price is $30.76 and its 200 day moving average price is $26.49.
GENMAB A/S/S Company Profile
Genmab A/S is a Denmark-based biotechnology company specializing in the creation and development of proprietary antibody therapeutics for the treatment of cancer and autoimmune diseases. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has focused on leveraging its innovative antibody platforms—such as DuoBody, HexaBody and DuoHexaBody—to generate next-generation therapies. The company’s expertise extends from early discovery through preclinical development, after which it partners with larger biopharmaceutical firms to advance candidates through clinical trials and commercialization.
Among Genmab’s most notable products is daratumumab, marketed under the brand name DARZALEX in collaboration with Janssen, which has become a leading monoclonal antibody for the treatment of multiple myeloma.
Featured Stories
- Five stocks we like better than GENMAB A/S/S
- How is Compound Interest Calculated?
- These 3 Banks Are Rallying Into Year-End, But Will It Continue?
- What is the S&P/TSX Index?
- 3 Surging Stocks Just Got the Ultimate Stamp of Approval From the S&P 500
- How to Plot Fibonacci Price Inflection Levels
- This ETF Caught a Major Tailwind After the Fed’s Rate Cut
Receive News & Ratings for GENMAB A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENMAB A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.
